• Je něco špatně v tomto záznamu ?

Fibroblast growth factors induce hepatic tumorigenesis post radiofrequency ablation

A. Markezana, M. Paldor, H. Liao, M. Ahmed, E. Zorde-Khvalevsky, N. Rozenblum, M. Stechele, L. Salvermoser, F. Laville, S. Goldmann, N. Rosenberg, T. Andrasina, J. Ricke, E. Galun, SN. Goldberg

. 2023 ; 13 (1) : 16341. [pub] 20230928

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc24001214

Grantová podpora
R01 CA197081 NCI NIH HHS - United States
CA197081-02 NIH HHS - United States
786575 European Research Council - International

Image-guided radiofrequency ablation (RFA) is used to treat focal tumors in the liver and other organs. Despite potential advantages over surgery, hepatic RFA can promote local and distant tumor growth by activating pro-tumorigenic growth factor and cytokines. Thus, strategies to identify and suppress pro-oncogenic effects of RFA are urgently required to further improve the therapeutic effect. Here, the proliferative effect of plasma of Hepatocellular carcinoma or colorectal carcinoma patients 90 min post-RFA was tested on HCC cell lines, demonstrating significant cellular proliferation compared to baseline plasma. Multiplex ELISA screening demonstrated increased plasma pro-tumorigenic growth factors and cytokines including the FGF protein family which uniquely and selectively activated HepG2. Primary mouse and immortalized human hepatocytes were then subjected to moderate hyperthermia in-vitro, mimicking thermal stress induced during ablation in the peri-ablational normal tissue. Resultant culture medium induced proliferation of multiple cancer cell lines. Subsequent non-biased protein array revealed that these hepatocytes subjected to moderate hyperthermia also excrete a similar wide spectrum of growth factors. Recombinant FGF-2 activated multiple cell lines. FGFR inhibitor significantly reduced liver tumor load post-RFA in MDR2-KO inflammation-induced HCC mouse model. Thus, Liver RFA can induce tumorigenesis via the FGF signaling pathway, and its inhibition suppresses HCC development.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24001214
003      
CZ-PrNML
005      
20240213094438.0
007      
ta
008      
240109s2023 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41598-023-42819-2 $2 doi
035    __
$a (PubMed)37770545
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Markezana, Aurelia $u The Goldyne Savad Institute of Gene and Cell Therapy, Hadassah Hebrew University Hospital, Ein Karem, Jerusalem, Israel. aureliahakoune@gmail.com
245    10
$a Fibroblast growth factors induce hepatic tumorigenesis post radiofrequency ablation / $c A. Markezana, M. Paldor, H. Liao, M. Ahmed, E. Zorde-Khvalevsky, N. Rozenblum, M. Stechele, L. Salvermoser, F. Laville, S. Goldmann, N. Rosenberg, T. Andrasina, J. Ricke, E. Galun, SN. Goldberg
520    9_
$a Image-guided radiofrequency ablation (RFA) is used to treat focal tumors in the liver and other organs. Despite potential advantages over surgery, hepatic RFA can promote local and distant tumor growth by activating pro-tumorigenic growth factor and cytokines. Thus, strategies to identify and suppress pro-oncogenic effects of RFA are urgently required to further improve the therapeutic effect. Here, the proliferative effect of plasma of Hepatocellular carcinoma or colorectal carcinoma patients 90 min post-RFA was tested on HCC cell lines, demonstrating significant cellular proliferation compared to baseline plasma. Multiplex ELISA screening demonstrated increased plasma pro-tumorigenic growth factors and cytokines including the FGF protein family which uniquely and selectively activated HepG2. Primary mouse and immortalized human hepatocytes were then subjected to moderate hyperthermia in-vitro, mimicking thermal stress induced during ablation in the peri-ablational normal tissue. Resultant culture medium induced proliferation of multiple cancer cell lines. Subsequent non-biased protein array revealed that these hepatocytes subjected to moderate hyperthermia also excrete a similar wide spectrum of growth factors. Recombinant FGF-2 activated multiple cell lines. FGFR inhibitor significantly reduced liver tumor load post-RFA in MDR2-KO inflammation-induced HCC mouse model. Thus, Liver RFA can induce tumorigenesis via the FGF signaling pathway, and its inhibition suppresses HCC development.
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    _2
$a zvířata $7 D000818
650    12
$a hepatocelulární karcinom $x patologie $7 D006528
650    12
$a nádory jater $x patologie $7 D008113
650    _2
$a fibroblastové růstové faktory $7 D005346
650    12
$a indukovaná hypertermie $7 D006979
650    12
$a radiofrekvenční ablace $x škodlivé účinky $7 D000078703
650    _2
$a karcinogeneze $7 D063646
650    _2
$a cytokiny $7 D016207
650    12
$a katetrizační ablace $7 D017115
655    _2
$a časopisecké články $7 D016428
655    _2
$a Research Support, N.I.H., Extramural $7 D052061
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Paldor, Mor $u The Goldyne Savad Institute of Gene and Cell Therapy, Hadassah Hebrew University Hospital, Ein Karem, Jerusalem, Israel
700    1_
$a Liao, Haixing $u The Goldyne Savad Institute of Gene and Cell Therapy, Hadassah Hebrew University Hospital, Ein Karem, Jerusalem, Israel
700    1_
$a Ahmed, Muneeb $u Laboratory for Minimally Invasive Tumor Therapies, Department of Radiology, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, MA, USA
700    1_
$a Zorde-Khvalevsky, Elina $u The Goldyne Savad Institute of Gene and Cell Therapy, Hadassah Hebrew University Hospital, Ein Karem, Jerusalem, Israel
700    1_
$a Rozenblum, Nir $u The Goldyne Savad Institute of Gene and Cell Therapy, Hadassah Hebrew University Hospital, Ein Karem, Jerusalem, Israel
700    1_
$a Stechele, Matthias $u The Goldyne Savad Institute of Gene and Cell Therapy, Hadassah Hebrew University Hospital, Ein Karem, Jerusalem, Israel $u Department of Radiology, University Hospital, LMU Munich, Munich, Germany
700    1_
$a Salvermoser, Lukas $u The Goldyne Savad Institute of Gene and Cell Therapy, Hadassah Hebrew University Hospital, Ein Karem, Jerusalem, Israel $u Department of Radiology, University Hospital, LMU Munich, Munich, Germany
700    1_
$a Laville, Flinn $u The Goldyne Savad Institute of Gene and Cell Therapy, Hadassah Hebrew University Hospital, Ein Karem, Jerusalem, Israel $u Department of Radiology, University Hospital, LMU Munich, Munich, Germany
700    1_
$a Goldmann, Salome $u The Goldyne Savad Institute of Gene and Cell Therapy, Hadassah Hebrew University Hospital, Ein Karem, Jerusalem, Israel
700    1_
$a Rosenberg, Nofar $u The Goldyne Savad Institute of Gene and Cell Therapy, Hadassah Hebrew University Hospital, Ein Karem, Jerusalem, Israel
700    1_
$a Andrasina, Tomas $u Department of Radiology and Nuclear Medicine, University Hospital Brno and Masaryk University Brno, Brno, Czech Republic
700    1_
$a Ricke, Jens $u Department of Radiology, University Hospital, LMU Munich, Munich, Germany
700    1_
$a Galun, Eithan $u The Goldyne Savad Institute of Gene and Cell Therapy, Hadassah Hebrew University Hospital, Ein Karem, Jerusalem, Israel
700    1_
$a Goldberg, Shraga Nahum $u The Goldyne Savad Institute of Gene and Cell Therapy, Hadassah Hebrew University Hospital, Ein Karem, Jerusalem, Israel. sgoldber@bidmc.harvard.edu $u Laboratory for Minimally Invasive Tumor Therapies, Department of Radiology, Beth Israel Deaconess Medical Center (BIDMC), Harvard Medical School, Boston, MA, USA. sgoldber@bidmc.harvard.edu $u Division of Image-Guided Therapy and Interventional Oncology, Department of Radiology, Hadassah Hebrew University Hospital, Jerusalem, Israel. sgoldber@bidmc.harvard.edu
773    0_
$w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 13, č. 1 (2023), s. 16341
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37770545 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213094435 $b ABA008
999    __
$a ok $b bmc $g 2049682 $s 1210908
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 13 $c 1 $d 16341 $e 20230928 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
GRA    __
$a R01 CA197081 $p NCI NIH HHS $2 United States
GRA    __
$a CA197081-02 $p NIH HHS $2 United States
GRA    __
$a 786575 $p European Research Council $2 International
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace